Observational study on managing blood-related side effects in breast cancer targeted therapies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, real-world observational study aims to collect data on hematological toxicities associated with targeted therapies for breast cancer. It will involve both retrospective and prospective data collection from 1000 patients, focusing on treatment cycles N and N+1. The study will analyze disease characteristics and management strategies for hematological toxicity, considering factors such as age, cancer subtype, and treatment regimens. The research respects the medication choices of the participating clinicians.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* · The patients signed the informed consent and voluntarily participated in the study.

  * A definite diagnosis of any type of breast cancer.
  * Receiving or has completed targeted therapies.
  * Investigator judged that the patient need to receive or had received treatment or prevention for CTIT, CIN or CRA induced by targeted therapies.

Exclusion Criteria:

* · Pregnant or lactating women.

  * Failure to understand the study or to obtain informed consent.
  * The investigator determined other situations that are not suitable for inclusion.

Where it's running

• Zhi-Ming Shao
  Shanghai, Not US/Canada, China Recruiting

Study contacts

• Principal investigator: Zhi-Ming Shao — Fudan University
• Study coordinator: Zhi-Ming Shao
• Email: zhi_ming_shao@163.com
• Phone: +86-021-64175590

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining targeted therapies for solid tumors using CDK4/6 inhibitors and anti-VEGF agents

  This study is testing if combining two cancer treatments, Palbociclib and Bevacizumab, can help people with solid tumors like colorectal, breast, and ovarian cancers feel better and respond better to treatment.

  Recruiting at 2 sites Phase 1 Lebanese University · Tripoli, North Lebanon and 1 other locations · NCT06307249

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Compare a new endoscopy-assisted breast-conserving surgery with the usual approach

  This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang and 21 other locations · NCT07920094

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.